- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06387498
Testicular Tissue Cryopreservation (TTC) (TTC)
April 25, 2024 updated by: University of Colorado, Denver
Testicular Tissue Cryopreservation for Fertility Preservation in Patients Facing Infertility-causing Diseases or Treatment Regimens.
The "Testicular Tissue Cryopreservation" study is open to a subset of patients facing disease or treatment regimens that could lead to infertility (gonadotoxic therapies).
For some of these patients, experimental testicular tissue cryopreservation is the only fertility preservation option available.
The overall objective of this study is to determine the feasibility and acceptability of testicular tissue cryopreservation in male patients of all ages who have a condition or will undergo a treatment that can cause infertility.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
For male patients who currently have no options for fertility preservation, this research proposal will enable optimization of testicular tissue procurement and processing, cryopreservation, and diagnosis/elimination of malignant cell contamination to ensure safety for future fertility-restoring treatments.
While results from animal models and human organ donor experiments support the efficacy of testicular tissue/cell cryopreservation for fertility preservation and subsequent restoration, rigorous safety and efficacy data in human patients who will undergo infertility-causing therapies is lacking.
However, the patients being recruited for this study currently have no options for future therapies aimed at fertility preservation without the preservation of their testicular tissue/cells prior to treatment.
Thus, the current study will provide a potential resource for future fertility restoration.
Study Type
Interventional
Enrollment (Estimated)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jocelyn Phipers
- Phone Number: 303-724-7807
- Email: Jocelyn.Phipers@cuanschutz.edu
Study Contact Backup
- Name: Leslie Appiah, MD
- Phone Number: 720-926-1970
- Email: LESLIE.APPIAH@CUANSCHUTZ.EDU
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Recruiting
- University of Colorado
-
Contact:
- Jocelyn Phipers, RN
- Phone Number: 303-724-7807
- Email: jocelyn.phipers@cuanschutz.edu
-
Contact:
- Leslie Appiah, MD
- Email: LESLIE.APPIAH@CUANSCHUTZ.EDU
-
Principal Investigator:
- Leslie Appiah, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male at any age.
Scheduled to undergo surgery, chemotherapy, drug treatment and/or radiation for the treatment or prevention of a medical condition or malignancy with risk of causing permanent and complete loss of subsequent testicular function. Be in significant risk of infertility as defined by:
- Cyclophosphamide equivalent dose (CED) ≥4 g/m2
- Total body irradiation (TBI)
- Testicular radiation >2.5 Gy
- Cisplatin 500 mg/m2
- Bone Marrow Transplant (BMT)
- Or have a medical condition or malignancy that requires removal of all or part of one or both testicles.
- Or have newly diagnosed or recurrent disease. Those who were not enrolled at the time of initial diagnosis (i.e., patients with recurrent disease) are eligible if they have not previously received therapy that is viewed as likely to result in complete and permanent loss of testicular function.
- Have two testicles if undergoing elective removal of a testicle for fertility preservation only. Note: removal of both testicles will limit fertility preservation options.
- Sign an approved informed consent and authorization permitting the release of personal health information. The patient and/or the patient's legally authorized guardian must acknowledge in writing that consent for specimen collection has been obtained, in accordance with institutional policies approved by the U.S. Department of Health and Human Services.
- Consent for serum tests for infectious diseases [including Hepatitis B Surface Antigen, HCV Antibody, and Human Immunodeficiency Virus (HIV) AG/AB Screen] to be performed at the time of testicular tissue harvesting.
- Undergo a full history and physical examination and obtain standard pre-operative clearance (based on the most recent ACC/AHA Guideline for Perioperative Cardiovascular Evaluation for Noncardiac Surgery) as determined by their primary surgeon.
Exclusion Criteria
Patients will be ineligible for participation in this study if they are:
- Diagnosed with psychological, psychiatric, or other conditions which prevent giving fully informed consent.
- Diagnosed with an underlying medical condition that significantly increases their risk of complications from anesthesia and surgery.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Testicular Tissue Cryopreservation
Enrolled participants will undergo a testicular tissue biopsy.
The method and amount of tissue procurement will be at the discretion of the surgeon.
|
Surgical Procurement of Testicular Tissue: At early stages of technology development, simple orchiectomy (removal of one entire testicle) may give the best chance of preserving sufficient cells for effective therapy.
However, incisional biopsy of up to 25% of tissue from one testis (wedge resection) will also be presented to the patient as an alternative option.
The amount of testicular parenchyma removed will be at the discretion of the surgeon.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility, as Assessed via the Percentage of Eligible Patients who do a Procedure
Time Frame: Up 3 months after prescribed gonadotoxic therapy
|
Determine feasibility of testicular tissue cryopreservation (TTC) in male patients receiving gonadotoxic therapies who desire fertility preservation.
Calculated by the percentage of eligible patients that elect to proceed with TTC.
|
Up 3 months after prescribed gonadotoxic therapy
|
Feasibility, as Assessed via Percentage of Patients who Attempted a Procedure who were able to Cryopreserve
Time Frame: Up to 48 hours after testicular tissue biopsy
|
Determine feasibility of testicular tissue cryopreservation (TTC) in male patients receiving gonadotoxic therapies who desire fertility preservation.
Calculated by the number of study participants whose tissue was successfully cryopreserved.
|
Up to 48 hours after testicular tissue biopsy
|
Safety, as Assessed via the Number of Participants with At Least One Pre-specified Adverse Event
Time Frame: Every six months throughout the life of the study (up to 7 years)
|
The investigators will determine the safety of testicular tissue cryopreservation (TTC) in male patients receiving gonadotoxic therapies who desire fertility preservation.
The number of participants with at least one of the following adverse events: 1) Bleeding, 2) Post-op infection, or 3) Long-term pain.
|
Every six months throughout the life of the study (up to 7 years)
|
Safety, as Assessed via the Number of Participants with At Least One Pre-specified Adverse Event
Time Frame: 24 hours of the procedure
|
The investigators will determine the safety of testicular tissue cryopreservation (TTC) in male patients receiving gonadotoxic therapies who desire fertility preservation.
The number of participants with bleeding.
|
24 hours of the procedure
|
Safety, as Assessed via the Number of Participants with At Least One Pre-specified
Time Frame: within 72 hours of the procedure
|
The investigators will determine the safety of testicular tissue cryopreservation (TTC) in male patients receiving gonadotoxic therapies who desire fertility preservation.
The number of participants with post-op infection.
|
within 72 hours of the procedure
|
Safety, as Assessed via the Number of Participants with At Least One Pre-specified
Time Frame: Assessed at 6 months
|
The investigators will determine the safety of testicular tissue cryopreservation (TTC) in male patients receiving gonadotoxic therapies who desire fertility preservation.
The number of participants with long-term pain.
|
Assessed at 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acceptability, as Assessed via Annual Survey Regret Score
Time Frame: Annually until the age of majority for the male participant
|
The Decision Regret Scale measures distress or remorse after a health care decision.
Possible scores range from 0-100, with higher scores indicating high regret.
|
Annually until the age of majority for the male participant
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Leslie Appiah, MD, University of Colorado, Denver
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 28, 2020
Primary Completion (Estimated)
December 30, 2027
Study Completion (Estimated)
December 30, 2027
Study Registration Dates
First Submitted
May 13, 2022
First Submitted That Met QC Criteria
April 25, 2024
First Posted (Actual)
April 29, 2024
Study Record Updates
Last Update Posted (Actual)
April 29, 2024
Last Update Submitted That Met QC Criteria
April 25, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20-2286
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fertility Issues
-
Charite University, Berlin, GermanyKarl and Veronica Carstens FoundationTerminatedFertility Issues | Fertility Disorders | IVF | Sub Fertility, Female | Sub-fertilityGermany
-
Carilion ClinicTerminatedFertility Issues | Fertility DisordersUnited States
-
IVFarma LLCInstitute for Preventive and Social MedicineCompletedFertility Issues | Fertility Disorders | IVF | Gynecologic Disease | Reproductive Issues | Reproductive DisorderRussian Federation
-
KK Women's and Children's HospitalNot yet recruitingFertility Issues | Reproductive Issues
-
Stanford UniversityRecruiting
-
Hadassah Medical OrganizationRecruiting
-
Port Said UniversityMansoura University; Prince Sattam Bin Abdulaziz UniversityRecruitingFertility IssuesEgypt
-
Istituto Clinico HumanitasCompleted
-
Regina Elena Cancer InstituteCompletedSurgery | Fertility Issues | OncologyItaly
Clinical Trials on Testicular tissue biopsy and cryopreservation
-
Gumy-Pause FabienneRecruitingChildhood Cancer | Fertility DisordersSwitzerland
-
Universitair Ziekenhuis BrusselRecruitingHematologic Diseases | Cancer | Sickle Cell ThalassemiaBelgium
-
Radboud University Medical CenterActive, not recruitingTurner Syndrome | Premature Ovarian Failure | Fertility Preservation | Live Birth | Ovarian Tissue CryopreservationNetherlands
-
University of EdinburghUniversity of OxfordRecruitingChildhood Cancer | Fertility DisordersUnited Kingdom
-
Fundación IVIRecruitingDNA Damage | IVF | Oligospermia | ICSI | EmbryoSpain
-
University of PittsburghWashington University School of Medicine; University of Miami; University of... and other collaboratorsRecruitingCancer | Autoimmune DisordersUnited States
-
Odense University HospitalCompleted
-
Cliniques universitaires Saint-Luc- Université...RecruitingInfertility, Male | Klinefelter SyndromeBelgium